NEXEL receives U.S. FDA acceptance of letter of intent for iPSC-derived cardiomyocyte platform ‘Cardiosight-S’
Nexel Leads the FDA Roadmap: Secures Full-Cycle Technologies from Organoid Development to Disease Modeling
FDA Unveils Roadmap to Reduce Animal Testing and Pave the Way for Human Stem Cell-Based Technologies
NEXEL "Leading the Way in Establishing 'Innovative Research and Development and Testing Methods' with Human-Induced Pluripotent Stem Cells"
NEXEL and Johns Hopkins University's Microphysiological Systems Sign MOU for 'Stem Cell and Organoid Research'
NEXEL and Japan's DNP collaborate on human-derived stem cell cardiomyocyte culture technology
NEXEL begins listing on KOSDAQ... Submission of request for preliminary evaluation
NEXEL, Establishes 'Nuoxinte Biotechnology' Branch in Suzhou, China
NEXEL Passes Technology Evaluation
BioHealth R&D Best Companies Awards
